The neurochemical mechanisms underlying sleep bruxism are little understood at present. However, recent pharmacologic evidence suggests that the central dopaminergic system may be involved in the pathophysiology of sleep bruxism. This possibility was further assessed by means of functional neuroimaging of dopamine D2 receptors with single-photon-emission computed tomography (SPECT). Ten controls and ten patients with polysomnographically confirmed sleep bruxism were injected intravenously with 185 MBq (5 mCi) iodine-123-iodobenzamide, a specific D2 receptor antagonist radioligand, and data acquisition was performed 90 min post-injection. Following image reconstruction, it was found that striatal D2 receptor binding potential (basal ganglia/background ratio) did not differ significantly between bruxism patients and controls. However, side-to-side differences between unilateral values of the striatal D2 binding potential ("highest side" values minus "lowest side" values) were significantly larger for the bruxism patients (p < 0.001, by two-independent-samples t test with pooled variances). It was concluded that an abnormal side imbalance in striatal D2 receptor expression can be associated with sleep bruxism. This reinforces the possibility that the central dopaminergic system plays a role in the pathophysiology of this disorder.
Ashcroft GW, Eccleston D., Waddell JL (1965). Recognition of amphetamine addicts (letter). Br Med J1:57.
2.
Briicke T., Podreka I., Angelberger P., Wenger S., Topitz A., Küfferle B., et al. (1991). Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab11:220-228.
3.
Brücke T., Wenger S., Asenbaum S., Fertl E., Pfafflmeyer N., Muller C., et al. (1993). Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol60:494-500.
4.
Castellano MA, Rodriguez Diaz M. (1991). Nigrostriatal dopaminergic cell activity is under control by substantia nigra of the contralateral brain side: Electrophysiological evidence. Brain Res Bull27:213-218.
5.
Costa DC, Verhoeff Npgl, Cullum ID, Ell PJ, Syed GM, Barrett J., et al. (1990). In vivo characterization of 3-iodo-6-methoxybenzamide 123-I in humans. Eur J Nucl Med16:813-816.
6.
Crutcher MD, DeLong MR (1984). Single cell studies of the primate putamen. Exp Brain Res53:233-243.
7.
Dettmar DM, Shaw RM, Tilley AJ (1987). Tooth wear and bruxism: A sleep laboratory investigation . Aust Dent J32:421-426.
8.
Geaney DP, Ellis PM, Soper N., Shepstone BJ, Cowen PJ (1992). Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol Psychiatry32:293-295.
9.
Hierholzer J., Cordes M., Schelosky L., Richter W., Keske U., Venz S., et al. (1994). Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med35:1921-1927.
10.
Ichise M., Toyama H., Fornazzari L., Ballinger JR, Kirsh JC (1993). Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med34:1274-1281.
11.
Innis RB, Malison RT, Al-Tikriti M., Hoffer PB, Sybiska EH, Seibyl JP, et al. (1992). Amphetamine-stimulated dopamine release competes in vivo for 123-I-IBZM binding to be D2 receptor in non-human primates . Synapse10:177-184.
12.
Knable MB, Jones DW, Coppola R., Hyde TM, Lee KS, Gorey J., et al. (1995). Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med36:1216-1225.
13.
Kung HF, Pan S., Kung M-P., Billings J., Kasliwal R., Reilley J., et al. (1989). In vitro and in vivo evaluation of 123-I-IBZM: A potential CNS D2 dopamine receptor imaging agent. J Nucl Med30:88-92.
14.
Lavigne GJ, Montplaisir JY (1994). Restless legs syndrome and sleep bruxism: Prevalence and association among Canadians. Sleep17:739-743.
15.
Lavigne GJ, Montplaisir JY (1995). Bruxism: Epidemiology, diagnosis, pathophysiology, and pharmacology. In: Orofacial pain and temporomandibular disorders. Fricton JR, Dubner RB, editors. New York, NY: Raven Press, pp. 387-404.
16.
Lavigne GJ, Lobbezoo F., Montplaisir JY (1995). The genesis of rhythmic masticatory muscle activity and bruxism during sleep. In: Brain and oral functions. Excerpta Medica International Congress series 1079. Morimoto T, Matsuva T, Takada K, editors. Amsterdam: Elsevier Science, pp. 249-255.
17.
Lavigne GJ, Rompre PH, Montplaisir JY (1996). Sleep bruxism: Validity of diagnostic criteria and motor variables in a controlled polysomnographic study. J Dent Res75:546-552.
18.
Lobbezoo F., Lavigne GJ, Tanguay R., Montplaisir JY (1996). The effect of the catecholamine precursor L-dopa on sleep bruxism: A controlled clinical trial. Mov Disord75:546-552.
19.
Magee KR (1970). Bruxism related to levodopa therapy (letter). J Am Med Assoc214:147.
20.
Nadeau SE, Couch MW, Devane CL, Shukla SS (1995). Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J Nucl Med36:384-393.
21.
Narang N., Hunt ME, Pundt LL, Alburges ME, Wamsley JK (1993). Unilateral ibotenic acid lesion of the caudate putamen results in D2 receptor alterations on the contralateral side. Exp Neurol121:40-47.
22.
Nishioka GJ, Montgomery MT, Boutros N., Haslam S. (1989). Dopaminergic modulation of nocturnal masticatory muscle EMG activity and sleep (abstract). J Dent Res68:391.
23.
Rechtschaffen A., Kales A. (1968). A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles, CA: UCLA Brain Information Service/ Brain Research Institute.
24.
Reding GR, Zepelin H., Robinson JE Jr, Zimmerman SO, Smith VH (1968). Nocturnal teeth-grinding: All-night psychophysiologic studies. J Dent Res47:786-797.
25.
Rodriguez M., Castellano MA, Palarea MD (1990). Interhemispheric regulation of dopaminergic ascending systems. Life Sci47:337-384.
26.
Rugh JD, Harlan J. (1988). Nocturnal bruxism and temporomandibular disorders . In: Advances in neurology. Vol. 49. Facial dyskinesias. Jankovic J, Tolosa E, editors. New York, NY: Raven Press, pp. 329-341.
27.
Schlosser R., Schlegel S. (1995). D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: A survey of current status. J Neural Transm [GenSect]99:173-185.
28.
Seeman P., van Tol Hhm (1994). Dopamine receptor pharmacology. TiPS15:264-270.
29.
Staedt J., Stoppe G., Kogler A., Munz D., Riemann H., Emrich D., et al. (1993). Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus). J Neural Transm [GenSect]93:71-74.
30.
Staedt J., Stoppe G., Kogler A., Riemann H., Hajak G., Munz DL, et al. (1995). Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm [GenSect]99:187-193.
31.
Strange PG (1993). Dopamine receptors in the basal ganglia: Relevance to Parkinson's disease. Mov Disord8:263-270.
32.
Thorpy MJ, editor (1990). Parasomnias. In: International classification of sleep disorders: Diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association, pp. 142-185.
33.
Verhoeff Nplg, Kapucu O, Sokole-Busemann E., van Royen EA, Janssen Agm (1993). Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: Technical and interobserver variability . J Nucl Med34:2076-2084.
34.
Winer BJ, Brown DR, Michels KM (1991). Statistical principles in experimental design . New York, NY: McGraw-Hill.
35.
Wong DF, Wagner HN Jr, Dannals RF, Links JM, Frost JJ, Ravert HT, et al. (1984). Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science226:1393-1396.
